Interaction Checker

Naldemedin etkileşimleri

opioid antagonisti sınıfından Naldemedin (Symproic) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 118 belgelenmiş etkileşim var: 75 majör, 41 orta, 0 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 2 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (75)

  • Alvimopanopioid antagonistiMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • AprepitantCYP3A4 inhibitörüMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • ArmodafinilMSS uyarıcısıMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • Belladonna ve afyonopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Biktegravir, emtrisitabin ve tenofovir alafenamidantiretroviralMajör

    Opioid Antagonist: Naloxegol ↑ naloxegol Avoid use with BIXLENVO; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (Biktegravir, emtrisitabin ve tenofovir alafenamid etiketi, İlaç etkileşimleri)

  • BosentanCYP3A4 indükleyicisiMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • BuprenorfinopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Buprenorfin ve naloksonopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Butalbital, aspirin, kafein ve kodeinbarbitüratMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Butalbital, parasetamol, kafein ve kodeinbarbitüratMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • ButorfanolopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • DarunavirantiretroviralMajör

    John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir… (Darunavir etiketi, Kontrendikasyonlar)

  • Darunavir ve kobisistatantiretroviralMajör

    John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is… (Darunavir ve kobisistat etiketi, Kontrendikasyonlar)

  • Deferasiroksdemir takviyesiMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • DeksametazonkortikosteroidMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • EfavirenzantiretroviralMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • Efavirenz, lamivudin ve tenofovirantiretroviralMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • EluksadolinopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • EslikarbazepinantikonvülsanMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • EtravirinantiretroviralMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • FenitoinantikonvülsanMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • FenobarbitalbarbitüratMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • FentanilopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Fentermin ve topiramatMSS uyarıcısıMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • FosfenitoinantikonvülsanMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • GriseofulvinantifungalMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • HidrokodonopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Hidrokodon ve homatropinopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Hidrokodon ve ibuprofenopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Hidrokodon ve klorfeniraminopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Hidrokodon ve parasetamolopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • HidromorfonopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • KarbamazepinantikonvülsanMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • KlobazambenzodiazepinMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • KodeinopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • LenakapavirantiretroviralMajör

    Opioid Antagonist: naloxegol ↑ naloxegol Avoid use with SUNLENCA; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (Lenakapavir etiketi, İlaç etkileşimleri)

  • LevorfanolopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Lopinavir ve ritonavirantiretroviralMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • LorlatinibCYP3A4 indükleyicisiMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • MetadonopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Metilnaltreksonopioid antagonistiMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • MitapivatCYP3A4 indükleyicisiMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • MitotanCYP3A4 indükleyicisiMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • ModafinilMSS uyarıcısıMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • MorfinopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Nafsilinpenisilin antibiyotikMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • NalbufinopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Nalmefenopioid antagonistiMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Naloksegolopioid antagonistiMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Naloksonopioid antagonistiMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Naltreksonopioid antagonistiMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Naltrekson ve bupropionopioid antagonistiMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • NevirapinantiretroviralMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • Nirmatrelvir ve ritonavirantiviralMajör

    …Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists: finerenone • Non-opioid analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin… (Nirmatrelvir ve ritonavir etiketi, Kontrendikasyonlar)

  • OksikodonopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Oksikodon ve parasetamolopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • OksimorfonopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • OkskarbazepinantikonvülsanMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • OliseridinopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Parasetamol ve kodeinopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Pentazosin ve naloksonopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • PetidinopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • PrimidonantikonvülsanMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • Prometazin ve kodeinopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • RemifentanilopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • RifabutinantibiyotikMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • RifampisinantibiyotikMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • RifapentinantibiyotikMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • RitonavirantiretroviralMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • SenobamatantikonvülsanMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • SuzetrijinCYP3A4 indükleyicisiMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • TapentadolopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • TopiramatantikonvülsanMajör

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Naldemedin etiketi, İlaç etkileşimleri)

  • TramadolopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

  • Tramadol ve parasetamolopioidMajör

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

Orta düzey etkileşimler (41)

  • AbrositinibJAK inhibitörüOrta

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Naldemedin etiketi, İlaç etkileşimleri)

  • AmiodaronantiaritmikOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • AtazanavirantiretroviralOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • Dekstrometorfan ve kinidinserotonerjik ilaçOrta

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Naldemedin etiketi, İlaç etkileşimleri)

  • Diltiazemkalsiyum kanal blokeriOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • DronedaronantiaritmikOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • Elvitegravir, kobisistat, emtrisitabin ve tenofovirantiretroviralOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • Eritromisinmakrolid antibiyotikOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • EverolimusimmünosüpresanOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • FlibanserinMSS depresanıOrta

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Naldemedin etiketi, İlaç etkileşimleri)

  • Flukonazolazol antifungalOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • FosamprenavirantiretroviralOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • FosaprepitantCYP3A4 inhibitörüOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • İmatinibCYP3A4 inhibitörüOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • İtrakonazolazol antifungalOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • İvakaftorCYP3A4 inhibitörüOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • İzoniazidantibiyotikOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • KaptoprilACE inhibitörüOrta

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Naldemedin etiketi, İlaç etkileşimleri)

  • Ketokonazolazol antifungalOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • KinidinantiaritmikOrta

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Naldemedin etiketi, İlaç etkileşimleri)

  • Klaritromisinmakrolid antibiyotikOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • LapatinibP-glikoprotein inhibitörüOrta

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Naldemedin etiketi, İlaç etkileşimleri)

  • Ledipasvir ve sofosbuvirantiviralOrta

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Naldemedin etiketi, İlaç etkileşimleri)

  • Lofeksidinalfa adrenerjik agonistOrta

    Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. (Lofeksidin etiketi, İlaç etkileşimleri)

  • MifepristonCYP3A4 inhibitörüOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • Mirabegronbeta adrenerjik agonistOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • NefazodonantidepresanOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • NilotinibQT aralığını uzatan ilaçOrta

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Naldemedin etiketi, İlaç etkileşimleri)

  • PalbosiklibCYP3A4 inhibitörüOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • PerampanelantikonvülsanOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • Posakonazolazol antifungalOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • PropafenonantiaritmikOrta

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Naldemedin etiketi, İlaç etkileşimleri)

  • RanolazinQT aralığını uzatan ilaçOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • SiklosporinimmünosüpresanOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • SimetidinH2 blokeriOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • Sofosbuvir ve velpatasvirantiviralOrta

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Naldemedin etiketi, İlaç etkileşimleri)

  • Suvoreksantsedatif-hipnotikOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • Tikagrelorantitrombosit ilaçOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • Verapamilkalsiyum kanal blokeriOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • Vorikonazolazol antifungalOrta

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

  • ZonisamidantikonvülsanOrta

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Naldemedin etiketi, İlaç etkileşimleri)

Anlamlı etkileşim olmadığı bildirilenler (2)

  • AkamprosatEtkileşim yok

    The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology ( 12.3 ) ]. (Akamprosat etiketi, İlaç etkileşimleri)

  • Emtrisitabin ve tenofovirantiretroviralEtkileşim yok

    No clinically significant drug interactions have been either observed or are expected when DESCOVY is combined with the following drugs: buprenorphine, itraconazole, ketoconazole, lorazepam, methadone, midazolam, naloxone, norbuprenorphine, norgestimate/ethinyl estradiol, and sertraline. (Emtrisitabin ve tenofovir etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Naldemedin ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.